Xiang An

1.8k citations
37 papers · 1.2k indexed · 1 hit paper · h-index 15
Topics
Hepatitis B Virus Studies (6 papers)Non-Invasive Vital Sign Monitoring (6 papers)Cancer-related molecular mechanisms research (5 papers)

In The Last Decade

Xiang An

36 papers receiving 1.2k citations

Hit Papers

STING: a master regulator in the cancer-immunity cycle2019202620212023201950100150200250

Peers

Xiang An
Comparison fields: 5 of 109
  • Molecular Biology 652
  • Immunology 418
  • Cancer Research 379
  • Oncology 193
  • Biomedical Engineering 133
Replace Lisha Mou with:
Lisha Mou China
Jun Ren United States
Pengfei Zhou China
Mayank Tandon United States
Lei Xu China
Suna Wang United States
Zhen Bian United States
Zhenhong Guo China
Yun Xue China
Jinyu Zhang China
Xiang An relative to Lisha Mou China Lisha Mou's profile →
Citations per field
00.5×2.8×
Lisha Mou · 1×
Citations per year

Countries citing papers authored by Xiang An

Since Specialization
Citations

This map shows the geographic impact of Xiang An's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiang An with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiang An more than expected).

Fields of papers citing papers by Xiang An

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiang An. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiang An. The network helps show where Xiang An may publish in the future.

Co-authorship network of co-authors of Xiang An

This figure shows the co-authorship network connecting the top 25 collaborators of Xiang An. A scholar is included among the top collaborators of Xiang An based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiang An. Xiang An is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 2
3 10
4 17
5 5
6 3
7 8
8 7
9
STING: a master regulator in the cancer-immunity cyclebreakdown →
298
10 8
11 32
12 125
13 283
14 29
15 55
16 28
17 19
18 10
19 2
20 46

About Xiang An

Xiang An is a scholar working on Cancer Research, Hepatology and Immunology, having authored 37 papers that have together received 1.2k indexed citations. Recurring topics across this work include Hepatitis B Virus Studies (6 papers), Non-Invasive Vital Sign Monitoring (6 papers) and Cancer-related molecular mechanisms research (5 papers). The work is most often cited by research in Cancer Research (379 citations), Immunology (418 citations) and Molecular Biology (652 citations). Xiang An has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Tongsen Zheng, Yuanyuan Zhu, Zheng‐Xiang Li, Yu Qiao, Xiao Zhang, Zifan Lu, Huilian Hou, Xu Li, Jingjing Pan and Wei Chen. Their work appears in journals such as Journal of Clinical Investigation, Scientific Reports and Biochemical and Biophysical Research Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026